Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06355531 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
A Phase 2 study of Progressive Supranuclear Palsy, sponsored by Ferrer Internacional S.A..
- Active
- Registry status
- Phase 2
- Development phase
- 241
- Enrollment target
- 20
- Study locations
NCT06355531 is a Phase 2 study of Progressive Supranuclear Palsy that is active but no longer recruiting, run by Ferrer Internacional S.A.. The registered enrollment target is 241 participants, below the 439-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06355531, a Phase 2 study of Progressive Supranuclear Palsy, is active but no longer recruiting, sponsored by Ferrer Internacional S.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 241 participants
- Enrollment target
- 20
- Study locations
Study Summary
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG FNP-223
Study Locations (20)
Other
- Groupe Hospitalier Pellegrin - Bordeaux
- Hôpital de la Timone - Marseille
- L'Hôpital Universitaire Carémeau - Nîmes
- Hôpital Universitaire Pitié Salpêtrière - Paris
- Hôpital Pierre-Paul Riquet - Toulouse
- Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson - Beelitz
- Universitätsklinikum Düsseldorf - Düsseldorf
- Universitätsklinikum Leipzig - Leipzig
California
- The Neurology Center of Southern California - Carlsbad - Carlsbad
- UCSF Weill Institute for Neurosciences - San Francisco
New York
- Robert & John M. Bendheim Parkinson and Movement Disorders Center at Mount Sinai - New York
- Columbia University Irving Medical Center - New York
Colorado
- Rocky Mountain Movement Disorders Center - Denver
Florida
- University of Miami Miller School of Medicine - Miami
Georgia
- Augusta University - Augusta
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Quest Research Institute - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06355531
The ClinicalTrials.gov registry entry for NCT06355531 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 18 other Progressive Supranuclear Palsy trials with a reported enrollment target (45% lower). The listed sponsor is Ferrer Internacional S.A., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Progressive Supranuclear Palsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06355531 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT06355531 about?
NCT06355531 is a clinical study titled "A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)". PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
What is the current status of trial NCT06355531?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 241 participants. The study started on 2024-07-23. Estimated completion is 2026-11.
What conditions does trial NCT06355531 study?
This clinical trial studies the following conditions: Progressive Supranuclear Palsy.
What interventions are being tested in trial NCT06355531?
The interventions under investigation include: Placebo (DRUG), FNP-223 (DRUG).
Who is sponsoring clinical trial NCT06355531?
This trial is sponsored by Ferrer Internacional S.A., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06355531 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Supranuclear Palsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMX0035 and Progressive Supranuclear Palsy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Coenzyme Q10 in PSP and CBD
COMPLETED · Phase 2
-
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
COMPLETED · Phase 2
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
-
Gait Analysis in Neurological Disease
RECRUITING
-
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.